GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares)Stock · Health Care

$52.17+$0.71 (+1.38%)as of market close, Aug 6, 2026

GSK financial statements

The full income statement, balance sheet, and cash-flow statement for GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2017-12 4.94B2018-12 4.97B2019-12 5.02B2020-12 4.03B2021-12 4.05B2022-12 4.08B2023-12 4.11B2024-12 4.14B2025-12 4.12B-16.7% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeYoYQoQFiguresAs-reported fiscal years.

Line item	FY2025	FY2024	FY2023	FY2022	FY2021
Income Statement	as ofDec 31 ’25	as ofDec 31 ’24	as ofDec 31 ’23	as ofDec 31 ’22	as ofDec 31 ’21
Revenue	43.1B YoY+7.6%	40.1B YoY+6.3%	37.7B YoY+4.3%	36.2B YoY+6.4%	34.0B YoY+8.7%
	31.2B YoY+9.4%	28.5B YoY+5.4%	27.1B YoY+11.0%	24.4B YoY+7.2%	22.7B YoY+7.9%
Cost of revenue	11.9B YoY+3.0%	11.6B YoY+8.6%	10.6B YoY-9.6%	11.8B YoY+4.9%	11.2B YoY+10.4%
Research & development	9.93B YoY+21.5%	8.18B YoY+5.7%	7.74B YoY+14.4%	6.77B YoY-2.0%	6.90B YoY+12.3%
Operating income	10.5B YoY+103.8%	5.14B YoY-38.7%	8.39B YoY+5.7%	7.93B YoY+32.3%	5.99B YoY-21.9%
Interest expense	925M YoY+8.3%	855M YoY-13.2%	985M YoY-9.1%	1.08B YoY+2.4%	1.06B YoY-5.6%
Pre-tax income	9.77B YoY+119.9%	4.44B YoY-41.1%	7.54B YoY+8.7%	6.94B YoY+40.1%	4.95B YoY-25.3%
Income tax	1.47B YoY+118.4%	672M YoY-28.5%	940M YoY+7.8%	872M YoY+663.3%	114M YoY+32.9%
	8.30B YoY+120.2%	3.77B YoY-42.9%	6.60B YoY-65.7%	19.3B YoY+174.7%	7.01B YoY-14.4%
Net income to common	7.55B YoY+129.3%	3.29B YoY-46.3%	6.13B YoY-66.8%	18.4B YoY+205.6%	6.03B YoY-18.2%
	$1.83 YoY+130.6%	$0.79 YoY-46.7%	$1.49 YoY-67.0%	$4.51 YoY+203.3%	$1.49 YoY-18.6%
EPS (basic)	$1.86 YoY+130.7%	$0.81 YoY-46.6%	$1.51 YoY-67.0%	$4.58 YoY+203.7%	$1.51 YoY-18.6%
	4.05B YoY-0.6%	4.08B YoY+0.6%	4.05B YoY+0.6%	4.03B YoY+0.6%	4.00B YoY+0.6%
	4.12B YoY-0.6%	4.14B YoY+0.8%	4.11B YoY+0.7%	4.08B YoY+0.8%	4.05B YoY+0.5%
Dividends per share	$0.87 YoY+11.8%	$0.78 YoY+8.1%	$0.72 YoY-4.5%	$0.76 YoY-45.1%	$1.38 YoY+7.2%
Balance Sheet	as ofDec 31 ’25	as ofDec 31 ’24	as ofDec 31 ’23	as ofDec 31 ’22	as ofDec 31 ’21
	23.6B YoY+10.3%	21.4B YoY-9.9%	23.7B YoY-5.2%	25.0B YoY-0.7%	25.2B YoY-7.8%
Cash & equivalents	4.57B YoY-6.0%	4.87B YoY+30.2%	3.74B YoY-16.7%	4.49B YoY-22.2%	5.77B YoY-32.1%
Accounts receivable	10.1B YoY+17.0%	8.60B YoY-8.6%	9.40B YoY+10.6%	8.50B YoY-19.9%	10.6B YoY+13.1%
Inventory	7.98B YoY+11.9%	7.13B YoY+1.9%	7.00B YoY+12.8%	6.20B YoY-20.5%	7.81B YoY-3.6%
	82.3B YoY+10.0%	74.8B YoY-0.5%	75.1B YoY+3.6%	72.5B YoY-32.1%	107B YoY-1.7%
Property, plant & equipment	12.6B YoY+8.1%	11.6B YoY+1.0%	11.5B YoY+6.6%	10.8B YoY-19.7%	13.4B YoY-2.4%
Goodwill	9.45B YoY+7.6%	8.78B YoY+1.3%	8.67B YoY+2.1%	8.49B YoY-40.4%	14.2B YoY-0.4%
Total non-current assets	58.7B YoY+9.9%	53.4B YoY+3.9%	51.4B YoY+8.3%	47.5B YoY-41.8%	81.6B YoY+0.4%
	28.8B YoY+5.5%	27.3B YoY+1.7%	26.8B YoY-2.4%	27.5B YoY-13.9%	32.0B YoY+6.9%
Short-term & current debt	4.06B YoY+37.3%	2.95B YoY-17.5%	3.58B YoY-24.8%	4.76B YoY-2.0%	4.86B YoY-3.3%
	60.8B YoY+4.2%	58.3B YoY-0.9%	58.8B YoY-2.5%	60.3B YoY-22.6%	78.0B YoY-3.1%
Long-term debt	19.8B YoY+7.6%	18.4B YoY-4.9%	19.4B YoY-5.7%	20.5B YoY-26.0%	27.8B YoY-12.2%
	22.1B YoY+28.2%	17.2B YoY+1.2%	17.0B YoY+33.0%	12.8B YoY-37.1%	20.3B YoY+3.2%
Total equity incl. non-controlling	21.5B YoY+30.5%	16.5B YoY+1.0%	16.3B YoY+33.9%	12.2B YoY-57.7%	28.8B YoY+2.6%
	4.32B YoY+0.0%	4.31B YoY+0.1%	4.31B YoY+0.0%	4.31B YoY-20.0%	5.39B YoY+0.0%
Cash Flow	as ofDec 31 ’25	as ofDec 31 ’24	as ofDec 31 ’23	as ofDec 31 ’22	as ofDec 31 ’21
	10.2B YoY+22.0%	8.37B YoY-0.5%	8.41B YoY-7.8%	9.13B YoY-16.6%	10.9B YoY+1.0%
Depreciation & amortization	3.05B YoY-6.3%	3.26B YoY+14.3%	2.85B YoY+7.7%	2.65B YoY-9.3%	2.92B YoY+11.0%
Acquisitions	0.00	0.00	0.00	0.00	0.00
Long-term debt issued	2.61B YoY+90.2%	1.37B YoY+395.5%	277M YoY-78.1%	1.26B	0.00 YoY-100.0%
Long-term debt repaid	1.85B YoY-10.4%	2.06B YoY-26.6%	2.81B YoY+43.0%	1.97B	0.00
Common stock issued	19.8M YoY-22.5%	25.6M YoY+105.6%	12.4M YoY-59.7%	30.8M YoY+6.7%	28.9M YoY-22.3%
Common stock repurchased	1.82B	0.00	0.00	0.00	0.00
Dividends paid	3.38B YoY+8.4%	3.12B YoY+11.8%	2.79B YoY-34.6%	4.27B YoY-22.3%	5.50B YoY+7.8%
Valuation Ratios	as ofDec 31 ’25	as ofDec 31 ’24	as ofDec 31 ’23	as ofDec 31 ’22	as ofDec 31 ’21
Market cap	202B YoY+44.1%	140B YoY-7.4%	151B YoY+6.3%	142B YoY-20.3%	179B YoY+20.5%
P/E	24.3× YoY-34.5%	37.1× YoY+372.7%	7.9× YoY-61.3%	20.3× YoY-20.3%	25.5× YoY+40.8%
P/S	4.7× YoY+34.0%	3.5× YoY-16.5%	4.2× YoY-0.1%	4.2× YoY-20.3%	5.3× YoY+10.8%
P/B	9.2× YoY+12.4%	8.1× YoY-31.2%	11.8× YoY+69.1%	7.0× YoY-20.3%	8.8× YoY+16.8%
	4.1% YoY+52.8%	2.7% YoY-78.8%	12.7% YoY+158.4%	4.9% YoY+25.5%	3.9% YoY-29.0%
	1.8% YoY-22.9%	2.3% YoY+18.5%	1.9% YoY-9.5%	2.1% YoY-31.1%	3.1% YoY-10.5%
Source filing	20-F	20-F	20-F	20-F	20-F

About this data

Source: GSK's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GSK filings on SEC EDGAR → Not investment advice.